Photo by tamba from unsplash
HIV-1 Integrase (IN) is a primary target for combination antiretroviral therapy (cART). Only a limited number of studies report on the emergence of resistance-associated mutations (RAMs) in Cameroon. We observed… Click to show full abstract
HIV-1 Integrase (IN) is a primary target for combination antiretroviral therapy (cART). Only a limited number of studies report on the emergence of resistance-associated mutations (RAMs) in Cameroon. We observed that (1.4%) of sequence from treatment naïve patients had Integrase strand transfer inhibitor (INSTI) RAMs. These mutations confer resistance to raltegravir (RAL) and elvitegravir (EVG). We also observed that 10.1% of the sequences have INSTI accessory RAMs. HIV-1 CRF02_AG was the predominant subtype (44.7.%) in this study analyses. The occurrence of INSTI RAMs among the sequences at baseline needs to be monitored carefully.
Journal Title: AIDS research and human retroviruses
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!